Indication intelligence, analysis and sector perception

Cytori Therapeutics (CYTX) P3 STAR study late-stage study of ECCS-50 in scleroderma 50% enrolled

March 24, 2016 10:05am

For the treatment of patients with impaired hand function due to scleroderma

Based on a pre-planned review of the safety data by the independent data monitoring committee, the P3 STAR study assessing lead product candidate ECCS-50 for the treatment of patients with impaired hand function due to scleroderma will continue as planned. The study is now 50% enrolled, with the 40^th patient treated.

The Bottom Line: The estimated final data collection date for the primary endpoint is July 2017. The estimated study completion date is December 2018. The primary endpoint is hand function at Week 24 versus placebo as measured by Cochin Hand Function Scale. The trial will continue as planned.

CYTX closed at $0.19 and is UP +$0.01, a “whopping 7.76%”. Reverse the shares to value the significance of good news to generate a better impact of the story.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

4 hours 8 min ago
RegMed Investors (RMi) Closing Bell: this week’s trend is an admission that the sector is without pricing sustainability suppressing a value directional

13 hours 9 min ago
RegMed Investors’ (RMi) pre-open: the down draft doesn’t seem to be over

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.